Get the Stockscreener App
12.79
1.23%
0.155
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Novavax Inc stock is traded at $12.79, with a volume of 4.20M.
It is up +1.23% in the last 24 hours and up +38.62% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$12.64
Open:
$12.5
24h Volume:
4.20M
Relative Volume:
0.37
Market Cap:
$2.11B
Revenue:
$596.34M
Net Income/Loss:
$-87.84M
P/E Ratio:
-21.41
EPS:
-0.5975
Net Cash Flow:
$-97.62M
1W Performance:
+16.21%
1M Performance:
+38.62%
6M Performance:
+47.24%
1Y Performance:
+43.60%
1-Day Range:
$12.18
$13.21
1-Week Range:
$11.03
$13.34
52-Week Range:
$6.20
$13.38
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
12.79 | 2.11B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Lobbying Update: $120,000 of NOVAVAX INC lobbying was just disclosed - Quiver Quantitative
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Zacks Investment Research
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada
Novavax Inc (Coinbase Tokenized Stock) - CryptoRank
Novavax, Inc.: Revenue and Earnings Analysts Forecasts Revisions | NVV1 | US6700024010 - marketscreener.com
Novavax, Inc. (NVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax Inc. Stock Rises 15.8%, Outperforms Peers - Webull
Novavax Inc (Coinbase Tokenized Stock) Analytics - CryptoRank
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies - Yahoo Finance
NVAX Stock Grinds Higher As Traders Watch Volatile Rebound - Timothy Sykes
Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside - TradingView
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax: Sell The False Plague Breakout (NASDAQ:NVAX) - Seeking Alpha
Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade - Yahoo Finance
Should Novavax’s Headline-Driven Volatility Around Russia Health Scare Require Action From NVAX Investors? - Yahoo Finance
Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks - Seeking Alpha
Novavax Inc (Coinbase Tokenized Stock) Price | NVAXc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Novavax Inc Tokenized Stock (Coinbase) price today, NVAXc to USD live price, marketcap and chart - CoinMarketCap
Transcript: Novavax Q2 2026 Earnings Conference Call - Benzinga
Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
NVAX Stock Slides As Momentum Traders Refocus On Fundamentals - StocksToTrade
Novavax Stock Falls Back: What's Going On? - Benzinga
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher - Yahoo Finance
Novavax, Moderna cool as WHO downplays plague-related death in Russia - Seeking Alpha
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Yahoo Finance
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety - Benzinga
Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today - Benzinga
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax Shorts on Edge as Russia Plague Fears Spread - Benzinga
Novavax, Inc. (NVAX) options chain - Yahoo Finance UK
Novavax, Inc. (NVV1.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
NVAX: Daily Falling Wedge Setup Eyeing $11.13 Ahead of Q3 for NASDAQ:NVAX by TaxpayerTrades - TradingView
Enterprise value to EBIT forward of Novavax, Inc. – BX:NVV1 - tradingview.com
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax stock falls 2.54 percent below its yearly high - AD HOC NEWS
Novavax Inc. Stock Rises 4.0%, Outperforms Peers - webull.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ruxandra Draghia Akli | Former Officer |
May 07 '26 |
Proposed Sale |
9.87 |
30,000 |
296,083 |
0 |
| Newton Charles W. | Director |
Apr 25 '26 |
Option Exercise |
0.00 |
9,520 |
0 |
9,520 |
| Shiver John W. | Director |
Mar 10 '26 |
Option Exercise |
0.00 |
7,947 |
0 |
7,947 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
2.63%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):